GAMUNEX-C ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
65	原発性免疫不全症候群	2

65. 原発性免疫不全症候群

---

臨床試験数 : 500 /  薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04561115 (ClinicalTrials.gov)	October 6, 2020	10/9/2020	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency	A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency	Primary Immunodeficiency	Biological: Gamunex-C;Biological: IVIG-PEG	Grifols Therapeutics LLC	NULL	Completed	18 Years	75 Years	All	36	Phase 3	United States
2	NCT01465958 (ClinicalTrials.gov)	November 2011	24/10/2011	Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency	An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency	Primary Immunodeficiency	Biological: GAMUNEX-C	Grifols Therapeutics Inc.	NULL	Completed	2 Years	16 Years	All	12	Phase 4	United States